Pharmacodynamic Study of Vemurafenib in the Neoadjuvant Setting in Patients With Locally Advanced Thyroid Cancer
Latest Information Update: 07 Nov 2023
At a glance
- Drugs Vemurafenib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 01 Nov 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2026.
- 01 Nov 2023 Planned primary completion date changed from 30 Sep 2022 to 30 Sep 2026.
- 03 Nov 2021 Planned End Date changed from 30 Nov 2020 to 30 Sep 2023.